Actively Recruiting
Phase I Study to Evaluate KP405 in Healthy and Parkinson's Disease Patients
Led by Kariya Pharmaceuticals · Updated on 2025-03-07
88
Participants Needed
1
Research Sites
86 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will explore the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of KP405 as a potential new treatment for Parkinson's disease.
CONDITIONS
Official Title
Phase I Study to Evaluate KP405 in Healthy and Parkinson's Disease Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy as determined by a responsible physician through medical history, physical exam, ECG, Holter monitoring, and lab tests
- Clinical diagnosis of Parkinson's disease meeting United Kingdom Brain Bank criteria
You will not qualify if you...
- History of significant physical or mental health issues interfering with study participation, excluding Parkinson's disease
- Neurologic disorders other than Parkinson's disease, including stroke or transient ischemic attack within 12 months
- Cognitive impairment
- Seizure within 5 years
- Head trauma with loss of consciousness within 6 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
MAC
Manchester, United Kingdom
Actively Recruiting
Research Team
I
Ian Laquian, MBA
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
11
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here